Daridorexant Trial Targets Insomnia and Alcohol Use Disorder
A clinical trial is underway to evaluate daridorexant's efficacy in reducing alcohol consumption and improving sleep in patients with insomnia and alcohol use disorder.
Phase III
Neurology / Sleep Disorders
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial of daridorexant could redefine treatment approaches for patients with both insomnia and alcohol use disorder, creating a potential dual-action therapy. Success in this trial may shift market dynamics and influence competitive positioning among existing therapies for these conditions.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy in reducing alcohol use and improving sleep metrics compared to placebo.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.